Makoto Maemondo Selected Research

Makoto Maemondo Research Topics

Disease

52	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2022 - 01/2003
27	Neoplasms (Cancer) 10/2022 - 01/2002
25	Lung Neoplasms (Lung Cancer) 08/2022 - 02/2002
13	Disease Progression 01/2022 - 01/2010
8	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2021 - 07/2006
7	Adenocarcinoma of Lung 08/2022 - 08/2008
6	Adenocarcinoma 10/2022 - 01/2002
6	Neutropenia 05/2019 - 07/2006
5	Neoplasm Metastasis (Metastasis) 01/2021 - 02/2002
4	Carcinoma (Carcinomatosis) 01/2022 - 05/2015
4	Interstitial Lung Diseases (Interstitial Lung Disease) 12/2021 - 08/2008
4	Febrile Neutropenia 05/2019 - 04/2014
3	Exanthema (Rash) 01/2019 - 06/2010
3	Pneumonia (Pneumonitis) 03/2015 - 08/2008
3	Infections 04/2012 - 07/2004
2	Diarrhea 05/2019 - 07/2006
2	Thrombocytopenia (Thrombopenia) 01/2017 - 07/2006
1	Meningeal Carcinomatosis 08/2022
1	Turcot syndrome 01/2021
1	Respiratory Sounds (Crackle) 10/2020
1	Laryngeal Neoplasms (Laryngeal Cancer) 10/2020
1	Cerebellar Ataxia (Dysmetria) 12/2019
1	Hypoxia (Hypoxemia) 03/2018
1	Asthma (Bronchial Asthma) 01/2018
1	Cryptogenic Organizing Pneumonia 01/2018
1	Idiopathic Pulmonary Fibrosis 01/2018
1	Anorexia 01/2017
1	Leukopenia 01/2017
1	Tumor Lysis Syndrome 10/2016

Drug/Important Bio-Agent (IBA)

26	ErbB Receptors (EGF Receptor)IBA 01/2022 - 01/2003
21	Tyrosine Kinase InhibitorsIBA 08/2022 - 08/2008
14	Gefitinib (Iressa)FDA Link 01/2022 - 01/2003
14	Carboplatin (JM8)FDA LinkGeneric 01/2021 - 07/2006
11	Erlotinib Hydrochloride (CP 358,774)FDA Link 08/2022 - 10/2013
11	PlatinumIBA 01/2021 - 01/2003
10	Proteins (Proteins, Gene)FDA Link 01/2022 - 02/2002
8	amrubicinIBA 01/2021 - 07/2006
7	Bevacizumab (Avastin)FDA Link 08/2022 - 10/2014
6	Pemetrexed (MTA)FDA Link 02/2021 - 09/2012
6	Paclitaxel (Taxol)FDA LinkGeneric 01/2017 - 06/2010
6	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 07/2005 - 02/2002
5	osimertinibIBA 08/2022 - 01/2020
5	NivolumabIBA 04/2022 - 01/2016
5	Docetaxel (Taxotere)FDA Link 09/2019 - 04/2014
5	AnthracyclinesIBA 12/2014 - 07/2006
4	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2016
4	Irinotecan (Camptosar)FDA LinkGeneric 01/2021 - 03/2013
4	alectinibIBA 03/2019 - 06/2013
3	Pharmaceutical PreparationsIBA 08/2022 - 06/2013
3	Biomarkers (Surrogate Marker)IBA 01/2022 - 05/2015
3	Cisplatin (Platino)FDA LinkGeneric 02/2021 - 07/2013
3	Anaplastic Lymphoma KinaseIBA 09/2018 - 01/2015
2	Biological ProductsIBA 10/2022 - 01/2016
2	AfatinibIBA 08/2022 - 01/2022
2	Trace Elements (Biometals)IBA 02/2021 - 11/2019
2	TegafurIBA 02/2021 - 07/2013
2	UracilIBA 02/2021 - 07/2013
2	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 07/2006
2	CarcinogensIBA 12/2018 - 09/2015
2	AntibodiesIBA 01/2018 - 11/2014
2	Peptides (Polypeptides)IBA 01/2016 - 02/2002
2	CrizotinibIBA 01/2015 - 06/2013
2	Vinorelbine (Navelbine)FDA LinkGeneric 04/2014 - 07/2013
2	CytokinesIBA 01/2005 - 07/2002
2	Angiogenesis InhibitorsIBA 07/2002 - 02/2002
1	IpilimumabIBA 04/2022
1	NucleotidesIBA 01/2021
1	Programmed Cell Death 1 ReceptorIBA 01/2021
1	Therapeutic UsesIBA 01/2021
1	Circulating Tumor DNAIBA 01/2020
1	SteroidsIBA 12/2019
1	pembrolizumabIBA 12/2019
1	ORALIT (ORS)IBA 01/2019
1	Glucose (Dextrose)FDA LinkGeneric 12/2018
1	CarbonIBA 12/2018
1	Protein Isoforms (Isoforms)IBA 12/2018
1	ceritinibIBA 09/2018
1	ThapsigarginIBA 03/2018
1	Endoplasmic Reticulum Chaperone BiPIBA 03/2018
1	D-Aspartic Acid (D Aspartate)IBA 03/2018
1	TransferasesIBA 03/2018
1	Protein D-Aspartate-L-Isoaspartate Methyltransferase (Protein L Isoaspartate D Aspartate O Methyltransferase)IBA 03/2018
1	Isoaspartic Acid (Isoaspartate)IBA 03/2018
1	ParaffinIBA 01/2018
1	Phosphotransferases (Kinase)IBA 05/2017
1	resminostatIBA 01/2017
1	Albumin-Bound Paclitaxel FDA Link 01/2017
1	130-nm albumin-bound paclitaxelIBA 01/2017
1	Histone Deacetylase InhibitorsIBA 01/2017
1	Hydroxamic Acids (Hydroxamic Acid)IBA 01/2017
1	Febuxostat FDA Link 10/2016
1	rasburicase (Elitek)FDA Link 10/2016

Therapy/Procedure

25	Drug Therapy (Chemotherapy) 04/2022 - 01/2003
18	Therapeutics 10/2022 - 02/2002
3	Radiotherapy 02/2021 - 07/2013
3	Immunotherapy 01/2021 - 05/2004
2	Aftercare (After-Treatment) 01/2022 - 10/2005
2	Molecular Targeted Therapy 08/2021 - 06/2014
2	Chemoradiotherapy 02/2021 - 10/2020
2	Intraperitoneal Injections 02/2005 - 02/2002